Technosphere inhaled insulin (afrezza)

M. Rendell

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Technosphere® insulin uses a unique carrier - fumaryl diketopiperazine (FDKP) - which adsorbs insulin to form microparticles to permit delivery to the alveoli by inhalation. Toxicity studies have been entirely negative. The pulmonary absorption of insulin is very rapid, and the disappearance time is shorter than for subcutaneously delivered rapid-acting insulins. As a result, after inhalation, there is a rapid drop in glucose levels which subsequently return to normal in a shorter time than after subcutaneous insulin administration. Consequently, there is a lower incidence of hypoglycemic reactions. Pulmonary function studies have shown a small, reversible decrease in FEV1, and pulmonary imaging studies have shown no adverse effect. The inhalation of Technosphere insulin can produce a cough in up to 27% of patients. The cough has resulted in discontinuance in as many as 9% of users. Technosphere insulin has been approved for use in type 1 and type 2 diabetes. Long-term studies of pulmonary safety and surveillance for malignancy will be performed in the future. Studies to assess the optimal time dosing regimen are needed.

Original languageEnglish
Pages (from-to)813-827
Number of pages15
JournalDrugs of Today
Volume50
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Insulin
Inhalation
Cough
Lung
Diketopiperazines
Short-Acting Insulin
Type 1 Diabetes Mellitus
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Safety
Glucose
Incidence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Technosphere inhaled insulin (afrezza). / Rendell, M.

In: Drugs of Today, Vol. 50, No. 12, 01.12.2014, p. 813-827.

Research output: Contribution to journalArticle

Rendell, M. / Technosphere inhaled insulin (afrezza). In: Drugs of Today. 2014 ; Vol. 50, No. 12. pp. 813-827.
@article{3c9c24f2bc5d455fb03d73e83a334466,
title = "Technosphere inhaled insulin (afrezza)",
abstract = "Technosphere{\circledR} insulin uses a unique carrier - fumaryl diketopiperazine (FDKP) - which adsorbs insulin to form microparticles to permit delivery to the alveoli by inhalation. Toxicity studies have been entirely negative. The pulmonary absorption of insulin is very rapid, and the disappearance time is shorter than for subcutaneously delivered rapid-acting insulins. As a result, after inhalation, there is a rapid drop in glucose levels which subsequently return to normal in a shorter time than after subcutaneous insulin administration. Consequently, there is a lower incidence of hypoglycemic reactions. Pulmonary function studies have shown a small, reversible decrease in FEV1, and pulmonary imaging studies have shown no adverse effect. The inhalation of Technosphere insulin can produce a cough in up to 27{\%} of patients. The cough has resulted in discontinuance in as many as 9{\%} of users. Technosphere insulin has been approved for use in type 1 and type 2 diabetes. Long-term studies of pulmonary safety and surveillance for malignancy will be performed in the future. Studies to assess the optimal time dosing regimen are needed.",
author = "M. Rendell",
year = "2014",
month = "12",
day = "1",
doi = "10.1358/dot.2014.50.12.2233894",
language = "English",
volume = "50",
pages = "813--827",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "12",

}

TY - JOUR

T1 - Technosphere inhaled insulin (afrezza)

AU - Rendell, M.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Technosphere® insulin uses a unique carrier - fumaryl diketopiperazine (FDKP) - which adsorbs insulin to form microparticles to permit delivery to the alveoli by inhalation. Toxicity studies have been entirely negative. The pulmonary absorption of insulin is very rapid, and the disappearance time is shorter than for subcutaneously delivered rapid-acting insulins. As a result, after inhalation, there is a rapid drop in glucose levels which subsequently return to normal in a shorter time than after subcutaneous insulin administration. Consequently, there is a lower incidence of hypoglycemic reactions. Pulmonary function studies have shown a small, reversible decrease in FEV1, and pulmonary imaging studies have shown no adverse effect. The inhalation of Technosphere insulin can produce a cough in up to 27% of patients. The cough has resulted in discontinuance in as many as 9% of users. Technosphere insulin has been approved for use in type 1 and type 2 diabetes. Long-term studies of pulmonary safety and surveillance for malignancy will be performed in the future. Studies to assess the optimal time dosing regimen are needed.

AB - Technosphere® insulin uses a unique carrier - fumaryl diketopiperazine (FDKP) - which adsorbs insulin to form microparticles to permit delivery to the alveoli by inhalation. Toxicity studies have been entirely negative. The pulmonary absorption of insulin is very rapid, and the disappearance time is shorter than for subcutaneously delivered rapid-acting insulins. As a result, after inhalation, there is a rapid drop in glucose levels which subsequently return to normal in a shorter time than after subcutaneous insulin administration. Consequently, there is a lower incidence of hypoglycemic reactions. Pulmonary function studies have shown a small, reversible decrease in FEV1, and pulmonary imaging studies have shown no adverse effect. The inhalation of Technosphere insulin can produce a cough in up to 27% of patients. The cough has resulted in discontinuance in as many as 9% of users. Technosphere insulin has been approved for use in type 1 and type 2 diabetes. Long-term studies of pulmonary safety and surveillance for malignancy will be performed in the future. Studies to assess the optimal time dosing regimen are needed.

UR - http://www.scopus.com/inward/record.url?scp=84919976233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919976233&partnerID=8YFLogxK

U2 - 10.1358/dot.2014.50.12.2233894

DO - 10.1358/dot.2014.50.12.2233894

M3 - Article

C2 - 25588086

AN - SCOPUS:84919976233

VL - 50

SP - 813

EP - 827

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 12

ER -